CLINICAL STUDY
Prospective crossover comparison of carvedilol and metoprolol in patients with chronic heart failure
Christoph Maack, MD*,
Thomas Elter, MD ,
Georg Nickenig, MD*,
Karl LaRosee, MD ,
Marina Crivaro, MD ,
Alexander Stäblein, MD ,
Henrike Wuttke, MD and
Michael Böhm, MD*
* Medizinische Klinik und Poliklinik, Innere Medizin III, Universitätskliniken des Saarlandes, Homburg, Germany
Klinik III für Innere Medizin, Universität zu Köln; Köln, Germany
Institut für Experimentelle und Klinische Pharmakologie und Toxikologie; Friedrich-Alexander Universität; Erlangen, Germany
Manuscript received January 22, 2001;
revised manuscript received May 17, 2001,
accepted June 11, 2001.
Reprint requests and correspondence: Dr. Christoph Maack, Medizinische Klinik und Poliklinik, Innere Medizin III, Universität des Saarlandes, 66421 Homburg/Saar, Germany maack{at}med-in.uni-saarland.de
OBJECTIVES
This study investigates the effects of a change of beta-adrenergic blocking agent treatment from metoprolol to carvedilol and vice versa in patients with heart failure (HF).
BACKGROUND
Beta-blockers improve ventricular function and prolong survival in patients with HF. It has recently been suggested that carvedilol has more pronounced effects on left ventricular ejection fraction (LVEF) compared with metoprolol. It is uncertain whether a change from one beta-blocker to the other is safe and leads to any change of left ventricular function.
METHODS
Forty-four patients with HF due to ischemic (n = 17) or idiopathic cardiomyopathy (n = 27) that had responded well to long-term treatment with either metoprolol (n = 20) or carvedilol (n = 24) were switched to an equivalent dose of the respective other beta-blocker. Before and six months after crossover of treatment, echocardiography, radionuclide ventriculography and dobutamine stress echocardiography were performed.
RESULTS
Six months after crossover of beta-blocker treatment, LVEF had further improved with both carvedilol and metoprolol (carvedilol: 32 ± 3% to 36 ± 4%; metoprolol: 27 ± 4% to 30 ± 5%; both p < 0.05 vs. baseline), without interindividual differences. There were no changes in either New York Heart Association functional class or any other hemodynamic parameters at rest. Dobutamine stress echocardiography revealed a more pronounced increase of heart rate after dobutamine infusion in metoprolol- compared with carvedilol-treated patients. After dobutamine infusion, LVEF increased in the carvedilol- but not in the metoprolol-treated group.
CONCLUSIONS
When switching treatment from one beta-blocker to the other, improvement of LVEF in patients with HF is maintained. Despite similar long-term effects on hemodynamics at rest, beta-adrenergic responsiveness is different in both treatments.
|
Abbreviations and Acronyms
| | betaARK1 | = beta-adrenergic receptor kinase 1 | | COMET | = Carvedilol Or Metoprolol European Trial | | DSE | = dobutamine stress echocardiography | | EDD | = end-diastolic diameter | | ESD | = end-systolic diameter | | HF | = heart failure | | LV | = left ventricle or left ventricular | | LVEF | = left ventricular ejection fraction | | NYHA | = New York Heart Association | | PCR | = polymerase chain reaction | | RNV | = radionuclide ventriculography | | Vcfc | = heart rate corrected velocity of circumferential shortening |
|
This article has been cited by other articles:

|
 |

|
 |
 
L. A. Nikolaidis, I. Poornima, P. Parikh, M. Magovern, Y.-T. Shen, and R. P. Shannon
The Effects of Combined Versus Selective Adrenergic Blockade on Left Ventricular and Systemic Hemodynamics, Myocardial Substrate Preference, and Regional Perfusion in Conscious Dogs With Dilated Cardiomyopathy
J. Am. Coll. Cardiol.,
May 2, 2006;
47(9):
1871 - 1881.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Di Lenarda, W. J. Remme, A. Charlesworth, J. G.F. Cleland, B. Lutiger, M. Metra, M. Komajda, C. Torp-Pedersen, A. Scherhag, K. Swedberg, et al.
Exchange of {beta}-blockers in heart failure patients. Experiences from the poststudy phase of COMET (the Carvedilol or Metoprolol European Trial)
Eur J Heart Fail,
June 1, 2005;
7(4):
640 - 649.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. F. McBride and C. M. White
Critical Differences Among Beta-Adrenoreceptor Antagonists in Myocardial Failure: Debating the MERIT of COMET
J. Clin. Pharmacol.,
January 1, 2005;
45(1):
6 - 24.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Rickli, S. Steiner, K. Muller, and O. M. Hess
Betablockers in heart failure: Carvedilol Safety Assessment (CASA 2-trial)
Eur J Heart Fail,
October 1, 2004;
6(6):
761 - 768.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Kindermann, C. Maack, S. Schaller, N. Finkler, K. I. Schmidt, S. Laer, H. Wuttke, H.-J. Schafers, and M. Bohm
Carvedilol but Not Metoprolol Reduces {beta}-Adrenergic Responsiveness After Complete Elimination From Plasma In Vivo
Circulation,
June 29, 2004;
109(25):
3182 - 3190.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Ahmed
Myocardial beta-1 adrenoceptor down-regulation in aging and heart failure: implications for beta-blocker use in older adults with heart failure
Eur J Heart Fail,
December 1, 2003;
5(6):
709 - 715.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E Bollano, M S. Tang, A Hjalmarson, F Waagstein, and B Andersson
Different responses to dobutamine in the presence of carvedilol or metoprolol in patients with chronic heart failure
Heart,
June 1, 2003;
89(6):
621 - 624.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|